Exagen Inc. (NASDAQ:XGN – Get Free Report) major shareholder Jorey Chernett sold 58,068 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $4.08, for a total transaction of $236,917.44. Following the completion of the transaction, the insider owned 2,529,436 shares of the company’s stock, valued at $10,320,098.88. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Thursday, November 12th, Jorey Chernett sold 109,436 shares of Exagen stock. The stock was sold at an average price of $4.65, for a total value of $508,877.40.
- On Wednesday, November 11th, Jorey Chernett acquired 71,315 shares of Exagen stock. The stock was purchased at an average price of $5.23 per share, for a total transaction of $372,977.45.
- On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The shares were sold at an average price of $6.14, for a total value of $69,167.10.
- On Tuesday, November 10th, Jorey Chernett bought 7,085 shares of Exagen stock. The stock was purchased at an average cost of $5.26 per share, with a total value of $37,267.10.
- On Monday, November 9th, Jorey Chernett bought 8,500 shares of Exagen stock. The stock was purchased at an average cost of $6.35 per share, with a total value of $53,975.00.
- On Monday, October 19th, Jorey Chernett bought 14,000 shares of Exagen stock. The shares were purchased at an average price of $7.46 per share, with a total value of $104,440.00.
Exagen Stock Performance
XGN stock opened at $4.13 on Monday. The company has a market cap of $105.37 million, a P/E ratio of -5.51 and a beta of 2.25. Exagen Inc. has a twelve month low of $2.59 and a twelve month high of $9.28. The company has a quick ratio of 3.46, a current ratio of 3.46 and a debt-to-equity ratio of 1.73. The business has a fifty day moving average of $7.71 and a 200-day moving average of $5.13.
Exagen (NASDAQ:XGN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.34 million. Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. As a group, equities research analysts expect that Exagen Inc. will post -0.71 EPS for the current year.
Top Exagen Stories
Here are a few of the latest stories about XGN:
- Positive Sentiment: BTIG reiterated its Buy rating. KeyCorp also forecasts a smaller loss in 2027 than in 2026, although it still expects Exagen to remain unprofitable. Article: Exagen’s Buy Rating Reiterated at BTIG Research
- Neutral Sentiment: Major shareholder Jorey Chernett recently made purchases as well as sales. KeyCorp’s 2026 loss estimate matches consensus, offering little change to current expectations.
- Negative Sentiment: Exagen’s latest quarterly loss per share was wider than analysts expected, even though revenue slightly beat estimates. Wall Street Zen downgraded the stock to Sell, while Canaccord lowered its price target from $11 to $9 but maintained a Buy rating. Article: Exagen Stock Rating Cut to Sell Article: Exagen Stock Gets Price Target Trim
Institutional Investors Weigh In On Exagen
Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LP bought a new stake in Exagen in the second quarter valued at about $52,000. Penbrook Management LLC acquired a new position in Exagen in the third quarter valued at about $92,000. Calamos Advisors LLC acquired a new position in Exagen in the third quarter valued at about $94,000. Bank of New York Mellon Corp bought a new position in Exagen during the second quarter worth about $97,000. Finally, Empowered Funds LLC bought a new position in Exagen during the third quarter worth about $198,000. 75.25% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
XGN has been the topic of several recent research reports. TD Cowen raised their target price on shares of Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. B. Riley Financial initiated coverage on shares of Exagen in a research note on Friday, September 11th. They set a “buy” rating and a $12.00 price target for the company. Canaccord Genuity Group dropped their price target on shares of Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Finally, Wall Street Zen cut shares of Exagen from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.88.
View Our Latest Stock Report on XGN
About Exagen
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
Featured Articles
- Five stocks we like better than Exagen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
